Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.72 USD
Change Today -0.10 / -1.72%
Volume 2.1M
PDLI On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 5:20 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

pdl biopharma inc (PDLI) Snapshot

Open
$5.85
Previous Close
$5.82
Day High
$5.90
Day Low
$5.66
52 Week High
09/2/14 - $10.26
52 Week Low
08/3/15 - $5.66
Market Cap
938.6M
Average Volume 10 Days
2.7M
EPS TTM
$1.95
Shares Outstanding
164.1M
EX-Date
09/2/15
P/E TM
2.9x
Dividend
$0.60
Dividend Yield
10.49%
Current Stock Chart for PDL BIOPHARMA INC (PDLI)

Related News

No related news articles were found.

pdl biopharma inc (PDLI) Related Businessweek News

No Related Businessweek News Found

pdl biopharma inc (PDLI) Details

PDL BioPharma, Inc. manages a portfolio of patents and royalty assets in the United States and Europe. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. PDL BioPharma, Inc. has license agreements with various biotechnology and pharmaceutical companies, as well as acquires royalty and other assets. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

10 Employees
Last Reported Date: 05/6/15
Founded in 1986

pdl biopharma inc (PDLI) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $716.1K
Chief Financial Officer and Vice President
Total Annual Compensation: $405.6K
Vice President, General Counsel and Secretary
Total Annual Compensation: $415.8K
Vice President of Business Development
Total Annual Compensation: $343.1K
Compensation as of Fiscal Year 2014.

pdl biopharma inc (PDLI) Key Developments

PDL BioPharma, Inc. Appoints Steffen Pietzke as Controller and Chief Accounting Officer

PDL BioPharma, Inc. announced that the company has appointed Steffen Pietzke, CPA, to the position of controller and chief accounting officer. Mr. Pietzkejoins PDL from Ernst & Young LLP (E&Y), where he held the position of senior manager since 2013. He provided audit and related financial services to both public and private companies in the U.S., Europe and China. Prior to joining E&Y, Mr. Pietzke was with PricewaterhouseCoopers LLP for more than 12 years, most recently as a senior manager.

PDL BioPharma, Inc. Presents at Nasdaq 32nd Investor Program, Jun-30-2015 08:30 AM

PDL BioPharma, Inc. Presents at Nasdaq 32nd Investor Program, Jun-30-2015 08:30 AM. Venue: May Fair Hotel, London, United Kingdom. Speakers: John Peter McLaughlin, Chief Executive Officer, President, Director and Member of Litigation Committee.

PDL BioPharma, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

PDL BioPharma, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, total revenue was $149.706 million against $136.804 million a year ago. Operating income was $142.040 million against $132.222 million a year ago. Income before income taxes was $133.516 million against $115.604 million a year ago. Net income was $84.498 million or $0.50 per diluted share against $72.883 million or $0.44 per diluted share a year ago. Net cash provided by operating activities was $71.846 million against $68.141 million a year ago. The increase in net income in the first quarter of 2015 over the same period in 2014 is primarily due to the increase in royalty revenues from the Queen et al. patents.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PDLI:US $5.72 USD -0.10

PDLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
arGEN-X BV €11.00 EUR -0.01
BioInvent International AB kr2.65 SEK +0.01
Genmab A/S kr655.00 DKK +15.50
XOMA Corp $0.77 USD +0.043
View Industry Companies
 

Industry Analysis

PDLI

Industry Average

Valuation PDLI Industry Range
Price/Earnings 3.0x
Price/Sales 1.9x
Price/Book 2.1x
Price/Cash Flow 2.9x
TEV/Sales 0.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PDL BIOPHARMA INC, please visit www.pdl.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.